ProMIS Neurosciences Inc. raised nearly C$1.5 million in proceeds related to an exercise of common stock warrants.
The warrants were exercised at 17 cents, 20 cents or 30 cents.
ProMIS is a Canadian biotechnology company focused on the discovery and development of precision treatments for neurodegenerative diseases, including amyotrophic lateral sclerosis. The company is focused on developing PMN310 for treating Alzheimer's disease.
